CeriBell (NASDAQ:CBLL – Get Free Report) has been assigned an average rating of “Buy” from the six brokerages that are covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $31.20.
A number of research analysts have weighed in on CBLL shares. William Blair started coverage on CeriBell in a report on Tuesday, November 5th. They set an “outperform” rating for the company. Canaccord Genuity Group lifted their target price on CeriBell from $30.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. JPMorgan Chase & Co. started coverage on CeriBell in a report on Tuesday, November 5th. They set an “overweight” rating and a $32.00 target price for the company. Bank of America started coverage on CeriBell in a report on Tuesday, November 5th. They set a “buy” rating and a $32.00 target price for the company. Finally, TD Cowen began coverage on CeriBell in a report on Tuesday, November 5th. They set a “buy” rating and a $31.00 target price for the company.
Read Our Latest Stock Analysis on CeriBell
CeriBell Stock Down 2.7 %
CeriBell (NASDAQ:CBLL – Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($1.03). The company had revenue of $17.20 million during the quarter, compared to analyst estimates of $17.06 million. On average, equities research analysts predict that CeriBell will post -2.46 earnings per share for the current year.
About CeriBell
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Featured Stories
- Five stocks we like better than CeriBell
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- How to Master Trading Discipline: Overcome Emotional Challenges
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Trump Tax Reforms: 7 Stocks That Could Benefit in 2025
- Pros And Cons Of Monthly Dividend Stocks
- 3 Stocks Near 52-Week Lows: Why They Could Be Smart Buys Today
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
